“Share hope. Hope sees the invisible, feels the intangible, and achieves the impossible—every day.”
Richard Pestell’s medical journey began at the University of Western Australia, where he graduated at the top of his class and earned an M.B., B.S. His initial clinical training continued as a physician in training at the Royal Perth Hospital and St Vincent's Hospital, Sydney. In these settings, he gained a busy and practical grounding in Internal Medicine and residency, including oncology, endocrinology, hematology, cardiology, and transplant medicine. This combination of broad clinical exposure and responsibility helped shape the direction of his future work in academic medicine and cancer research, grounded in clinical purpose.
His interest in cancer biology led him to pursue deeper scientific training and focus on the mechanisms that drive disease. He completed a Ph.D. at the University of Melbourne's Howard Florey Institute, specializing in the regulation of oncogene transcription. This research foundation supported his later ability to connect scientific discovery with clinical goals while maintaining a steady focus on accuracy, method, and relevance as he examined complex biological systems.
Richard’s academic excellence was rewarded with national scholarships and multiple competitive fellowships, including a Winthrop Fellowship and an NHMRC postgraduate award. These achievements led him to Harvard Medical School and Massachusetts General Hospital, where he trained further as a clinical and research fellow. In those roles, he continued to build skills that enabled him to integrate patient care priorities with research questions central to oncology and translational medicine.
Academic Leadership and Scientific Influence
Richard Pestell continued his academic career at Northwestern University and then at the Albert Einstein College of Medicine. Over time, he became a Professor, Chair of the Division of Endocrine-Dependent Tumor Biology, and Co-Director of major cancer research programs. He also held positions at multiple hospitals in New York, which enabled him to remain closely engaged in patient care and medical education while guiding academic programs and research teams.
His research contributed to cancer therapeutics by informing scientific understanding that supports clinical development. His research on cyclin D1 was cited in the seminal publications underpinning CDK inhibitor clinical trials and their adoption as a standard therapy for breast cancer globally. His work emphasized careful evidence and precise interpretation, with attention to how research findings can support clinical decision-making and future studies, and through sustained scientific rigor.
He also produced research on CCR5 that provided the scientific framework for current oncology clinical trials with CCR5 inhibitors. Throughout his career, he has published over 700 works, received more than 110,000 citations, and achieved an h-index of 162. He has also given extensive invited lectures around the world, reflecting his ongoing scientific contributions and collaborations in cancer biology and related fields.
Directing Major Cancer Centers
Richard Pestell became the Director of the Lombardi Comprehensive Cancer Center at Georgetown University in 2002. He also served as Chair of the Department of Oncology and Associate Vice President at Georgetown University Medical Center. In this capacity, he was responsible for research direction, clinical operations, and faculty development, and he contributed to institutional restructuring and growth that supported expanded cancer center capabilities.
He worked to build community partnerships, enhance research programs, and expand clinical services across Georgetown and MedStar systems. These responsibilities demanded coordination across clinical leadership, research groups, administrative planning, and community engagement, with an emphasis on sustainable growth and continuous improvement in patient-focused services.
Richard took on additional leadership roles in 2005 as the Director of the Sidney Kimmel Cancer Center, Chair of the Department of Cancer Biology, and head of the Oncology Service Line at Thomas Jefferson University. His responsibilities broadened across clinical care strategy, research infrastructure, and program development, requiring careful alignment of teams and clear organizational direction across the cancer enterprise.
He later became the Executive Vice President, charged with enterprise-wide strategic decisions across a system of 30,000 employees. At Jefferson, he directed an overall cancer enterprise with an annual budget of> $350 m and led transformational efforts in clinical care, research infrastructure, regional expansion, and team building. Under his tenure, the cancer center rose from 64 to 17, reflecting measurable progress across key performance and program areas.
Academic Appointments and Global Engagement
Richard Pestell has also held leadership roles in academia outside of the US, supporting education, research, and outreach initiatives with an international scope. He was a founding Director of the Delaware Valley Institute for Clinical and Translational Science, helped develop new education pathways for historically black colleges, and led global cancer outreach at the International Network for Cancer Treatment and Research. These roles demonstrate a continued focus on collaboration, training opportunities, and strengthening cancer programs across different settings.
He has served on faculty or advisory boards with the University of Melbourne, the University of Western Australia, Nanyang Technological University, Xavier University School of Medicine, Kazan Federal University, and several European institutions. Through these affiliations, he has supported academic planning, advisory work, and research and education collaborations, contributing to shared goals across institutions and countries.
Richard’s election to and service with prominent scientific bodies reflect the global reach of his work. He has served at the Academia Europaea, the Hungarian Academy of Sciences, the American Society for Clinical Investigation, and the Royal Society of Biology, among others. His awards included the RD Wright Medallion and the Eric Susman Prize in Medicine, culminating in his being made an Officer of the Order of Australia in 2019.
Building Companies and Advancing Innovation
Richard Pestell has a long history of entrepreneurship alongside academic leadership. He is the founder of six biotechnology companies: LightSeed, ProstaGene (acquired in 2018), EcoGenome, StromaGenesis, ioROC, and Shenandoah Pharmaceuticals. Along with these ventures, he has raised nearly 50 million dollars from investors, plus more than 80 million dollars as a principal investigator on NIH research grants. These figures reflect substantial effort in building research-supported innovation while guiding organizations focused on biotechnology development.
His patent portfolio has included discoveries in molecular diagnostics, cancer prognostics, therapeutic methods, and novel technologies that have impacted academic and commercial drug discovery and development. He has served in advisory capacities for organizations such as the National Academy of Inventors, CytoDyn, Novartis, Deloitte, and numerous health technology companies. Through these advisory roles, he has gained experience in research translation, development strategy, and applying scientific work to practical solutions.
Philanthropy, Community Service, and Cultural Engagement
Richard Pestell has made community engagement a consistent priority. At Georgetown and Jefferson, he led philanthropic efforts that produced transformational gifts and created new ways to sustain ongoing fundraising in support of cancer care, wellness centers, and community outreach initiatives for patients and families. These activities helped strengthen services that support patients and families and also developed resources to sustain long-term community programs.
He has served on different boards, including the National Museum of American Jewish History, the Chamber Orchestra of Philadelphia, the Jewish Federation of Greater Philadelphia, the Historic St. Peter’s Church Preservation Corporation, the American Cancer Society committees, and several university societies. This board service reflects a steady commitment to cultural institutions, community-focused organizations, and public health-related efforts tied to education and outreach.
Richard also supported the Olivia Newton-John Wellness Center through a fundraising trek on The Great Wall. This effort combined fundraising with personal participation and reinforced the importance of public support for wellness initiatives connected to cancer care.
A Continuing Commitment to Science and Human Health
Richard Pestell now serves as President of the Pennsylvania Cancer and Regenerative Medicine Center, Blumberg Distinguished Professor of Translational Medical Research at the Baruch Blumberg Institute, and a member of the Wistar Institute Cancer Center. He still supports global cancer programs, mentors scientific leaders, and develops technologies for improved diagnostics and treatment. His current work reflects ongoing attention to translational medical research and the practical steps needed to move discovery toward clinical benefit.
He continues to use scientific insight with a practical approach to enhance the quality of patient care and institutions, and to broaden the reach of modern oncology. Richard’s extensive work continues to influence cancer research, education, and biotechnology on a global scale through sustained leadership, continued research involvement, and ongoing commitment to collaboration and service.
Books Authored and Contributed to by Richard Pestell:
Molecular Endocrinology: Basic Concepts and Clinical Correlations
Read the Molecular Endocrinology book
Oncogenes
Read Oncogenes research book
Cancer Epigenetics: Biomolecular Therapeutics for Human Cancer
Read the Cancer Epigenetics book
Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies
Read the Prostate Cancer research book
Molecular Targeting and Signal Transduction (Cancer Treatment and Research, Vol. 119)
Read the Molecular Targeting book
Signal Transduction Protocols (Kindle Edition)
Read Signal Transduction Protocols
Molecular Targeting in Oncology
Read Molecular Targeting in Oncology
Cell Cycle Checkpoint Control Protocols (Methods in Molecular Biology, Vol. 241)
Read the Cell Cycle Checkpoint Control book
Methods in Enzymology
Read Methods in Enzymology volume
D-type Cyclins and Cancer
Read the D-type Cyclins and Cancer book
Hormonal Control of Cell Cycle
Read the Hormonal Control of Cell Cycle book